Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.

[1]  C. Spencer,et al.  Biological Insights From 108 Schizophrenia-Associated Genetic Loci , 2014, Nature.

[2]  Jennifer G. Robinson,et al.  Quantifying rare, deleterious variation in 12 human cytochrome P450 drug-metabolism genes in a large-scale exome dataset. , 2014, Human molecular genetics.

[3]  H. Tornqvist,et al.  Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial , 2014, Diabetes, obesity & metabolism.

[4]  C. Altar,et al.  The social and economic burden of treatment-resistant schizophrenia: a systematic literature review , 2014, International clinical psychopharmacology.

[5]  M. Leboyer,et al.  Comparative analysis of anti-toxoplasmic activity of antipsychotic drugs and valproate , 2014, European Archives of Psychiatry and Clinical Neuroscience.

[6]  Eric S. Lander,et al.  A polygenic burden of rare disruptive mutations in schizophrenia , 2014, Nature.

[7]  David S. Wishart,et al.  DrugBank 4.0: shedding new light on drug metabolism , 2013, Nucleic Acids Res..

[8]  P. Johnston,et al.  Cancer drug resistance: an evolving paradigm , 2013, Nature Reviews Cancer.

[9]  S. Leucht,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis (vol 382, pg 951, 2013) , 2013 .

[10]  Dimitris Mavridis,et al.  Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis , 2013, The Lancet.

[11]  Simon C. Potter,et al.  Genome-wide Association Analysis Identifies 14 New Risk Loci for Schizophrenia , 2013, Nature Genetics.

[12]  M. De Hert,et al.  Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review , 2013, Therapeutic advances in psychopharmacology.

[13]  P. DeRosse,et al.  Genetic variation in BDNF is associated with antipsychotic treatment resistance in patients with schizophrenia , 2013, Schizophrenia Research.

[14]  Robert V Farese,et al.  DGAT1 mutation is linked to a congenital diarrheal disorder. , 2012, The Journal of clinical investigation.

[15]  R. Altman,et al.  Pharmacogenomics Knowledge for Personalized Medicine , 2012, Clinical pharmacology and therapeutics.

[16]  Colm O'Dushlaine,et al.  INRICH: interval-based enrichment analysis for genome-wide association studies , 2012, Bioinform..

[17]  G. Remington,et al.  Treatment resistant schizophrenia and response to antipsychotics: A review , 2011, Schizophrenia Research.

[18]  J. Kleinman,et al.  Spatiotemporal transcriptome of the human brain , 2011, Nature.

[19]  A. Malhotra,et al.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction , 2011, Expert opinion on drug metabolism & toxicology.

[20]  Tanya M. Teslovich,et al.  Biological, Clinical, and Population Relevance of 95 Loci for Blood Lipids , 2010, Nature.

[21]  Michael J. Keiser,et al.  Predicting new molecular targets for known drugs , 2009, Nature.

[22]  J. McGrath,et al.  Schizophrenia: a concise overview of incidence, prevalence, and mortality. , 2008, Epidemiologic reviews.

[23]  Dolores Corella,et al.  Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans , 2008, Nature Genetics.

[24]  Anders Sundström,et al.  The new Swedish Prescribed Drug Register—Opportunities for pharmacoepidemiological research and experience from the first six months , 2007, Pharmacoepidemiology and drug safety.

[25]  R. Yolken,et al.  Antibodies to Toxoplasma gondii in patients with schizophrenia: a meta-analysis. , 2007, Schizophrenia bulletin.

[26]  Michael J. Keiser,et al.  Relating protein pharmacology by ligand chemistry , 2007, Nature Biotechnology.

[27]  Patrick F Sullivan,et al.  Recurrence risks for schizophrenia in a Swedish National Cohort , 2006, Psychological Medicine.

[28]  J. Lieberman,et al.  Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. , 2005, The New England journal of medicine.

[29]  B. Hawes,et al.  The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[30]  D. Russell,et al.  Clinical importance of the cytochromes P450 , 2002, The Lancet.

[31]  J. Darnell,et al.  Fragile X Mental Retardation Protein Targets G Quartet mRNAs Important for Neuronal Function , 2001, Cell.

[32]  E. Hewlett,et al.  Lethal effect of phenothiazine neuroleptics on the pathogenic protozoan Leishmania donovani. , 1982, Science.

[33]  Mulin Jun Li,et al.  Nature Genetics Advance Online Publication a N a Ly S I S the Support of Human Genetic Evidence for Approved Drug Indications , 2022 .